Hospodárske výsledky spoločnosti Inhibrx
Aká je hodnota metriky Hospodárske výsledky spoločnosti Inhibrx?
Hodnota metriky Hospodárske výsledky spoločnosti Inhibrx, Inc. je N/A
Aká je definícia metriky Hospodárske výsledky?
Dátum zverejnenia hospodárskych výsledkov (Earnings date) je dátum ďaľšieho zverejnenia finančnej správy spoločnosti.
Earnings report date is the date of an official announcement about a company's profitability for a specific time period. In the private sector, a quarterly finance report is a financial report that covers three months of the year, which is required by numbers of stock exchanges around the world to provide information to investors on the state of a company.
Čomu sa venuje spoločnosť Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.